Compare Quest Diagnostics Inc (DGX) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Spotify Technology — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Spotify Technology trades at $481.83 (market cap $98.92B). The key difference: Spotify Technology is far larger — about 4.3× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Spotify Technology pays none. Which is the better fit depends on your goals.
| DGX | SPOT | |
|---|---|---|
Market Cap | $22.80B | $98.92B |
Sector | Health | Media |
52-Week High | $216.02 | $738.53 |
52-Week Low | $166.42 | $412.75 |
Enterprise Value | $28.82B | $89.50B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Spotify (SPOT) trades at $479.84, showing minimal daily movement (+0.01%) amid neutral technical signals. The company demonstrates strong fundamental momentum with revenue growing from $11.7B in 2022 to $17.2B in 2025, while achieving profitability turnaround from losses to $2.2B net income. Recent earnings beats and AI integration initiatives highlight operational strength, though technical indicators show mixed signals with bearish moving averages and neutral oscillators.
Spotify presents a compelling growth story with accelerating profitability and analyst optimism (61.5% buy ratings), though faces execution risks in competitive streaming markets. The stock trades at a premium valuation (P/E 32.7) but offers 28% upside to consensus target of $617. Key risks include market saturation and royalty cost pressures, while AI innovation provides growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
